Revance Therapeutics, Inc. provided revenue guidance for the year 2024. The company expects 2024 total product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least $280 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.27 USD | -2.51% | +12.52% | -51.42% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.42% | 445M | |
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-15.09% | 31.99B | |
+51.96% | 24.73B | |
-15.13% | 15.54B | |
-8.63% | 12.05B | |
-40.39% | 12.07B | |
+6.22% | 8.84B | |
-5.15% | 8.3B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024